Skip to main content

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Publication ,  Journal Article
Preiss, D; Giles, TD; Thomas, LE; Sun, J-L; Haffner, SM; Holman, RR; Standl, E; Mazzone, T; Rutten, GE; Tognoni, G; Chiang, F-T; McMurray, JJV ...
Published in: Stroke
September 2013

BACKGROUND AND PURPOSE: Risk factors for stroke are well-established in general populations but sparsely studied in individuals with impaired glucose tolerance. METHODS: We identified predictors of stroke among participants with impaired glucose tolerance in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Cox proportional-hazard regression models were constructed using baseline variables, including the 2 medications studied, valsartan and nateglinide. RESULTS: Among 9306 participants, 237 experienced a stroke over 6.4 years. Predictors of stroke included classical risk factors such as existing cerebrovascular and coronary heart disease, higher pulse pressure, higher low-density lipoprotein cholesterol, older age, and atrial fibrillation. Other factors, including previous venous thromboembolism, higher waist circumference, lower estimated glomerular filtration rate, lower heart rate, and lower body mass index, provided additional important predictive information, yielding a C-index of 0.72. Glycemic measures were not predictive of stroke. Variables associated with stroke were similar in participants with no prior history of cerebrovascular disease at baseline. CONCLUSIONS: The most powerful predictors of stroke in patients with impaired glucose tolerance included a combination of established risk factors and novel variables, such as previous venous thromboembolism and elevated waist circumference, allowing moderately effective identification of high-risk individuals.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Stroke

DOI

EISSN

1524-4628

Publication Date

September 2013

Volume

44

Issue

9

Start / End Page

2590 / 2593

Location

United States

Related Subject Headings

  • Valsartan
  • Valine
  • Tetrazoles
  • Stroke
  • Risk Factors
  • Predictive Value of Tests
  • Phenylalanine
  • Outcome Assessment, Health Care
  • Neurology & Neurosurgery
  • Nateglinide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Preiss, D., Giles, T. D., Thomas, L. E., Sun, J.-L., Haffner, S. M., Holman, R. R., … Califf, R. M. (2013). Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Stroke, 44(9), 2590–2593. https://doi.org/10.1161/STROKEAHA.113.001177
Preiss, David, Thomas D. Giles, Laine E. Thomas, Jie-Lena Sun, Steven M. Haffner, Rury R. Holman, Eberhard Standl, et al. “Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.Stroke 44, no. 9 (September 2013): 2590–93. https://doi.org/10.1161/STROKEAHA.113.001177.
Preiss, David, et al. “Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.Stroke, vol. 44, no. 9, Sept. 2013, pp. 2590–93. Pubmed, doi:10.1161/STROKEAHA.113.001177.
Preiss D, Giles TD, Thomas LE, Sun J-L, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang F-T, McMurray JJV, Califf RM. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Stroke. 2013 Sep;44(9):2590–2593.

Published In

Stroke

DOI

EISSN

1524-4628

Publication Date

September 2013

Volume

44

Issue

9

Start / End Page

2590 / 2593

Location

United States

Related Subject Headings

  • Valsartan
  • Valine
  • Tetrazoles
  • Stroke
  • Risk Factors
  • Predictive Value of Tests
  • Phenylalanine
  • Outcome Assessment, Health Care
  • Neurology & Neurosurgery
  • Nateglinide